Moore Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Moore Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-19,501	Closed	-$676K	–	832
2022 Q1	$676K	Buy	+19,501	New	+$583K	0.02%	447
2021 Q1	–	Sell	-86,915	Closed	-$3.76M	–	844
2020 Q4	$3.76M	Sell	86,915 -24,830	-22%	-$1.22M	0.04%	294
2020 Q3	$6.16M	Buy	+111,745	New	+$7.1M	0.12%	164
2017 Q1	–	Sell	-75,000	Closed	-$1.08M	–	246
2016 Q4	$1.08M	Buy	+75,000	New	+$1.32M	0.04%	146
2016 Q1	–	Sell	-40,000	Closed	-$1.29M	–	356
2015 Q4	$1.29M	Buy	+40,000	New	+$1.73M	0.04%	234

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Moore Capital Management's GBT Position: Q2 2022 in Review

Moore Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 19,501 shares — an estimated $676K sold.

Moore Capital Management first reported a position in GBT in Q4 2015 and held it in 5 quarters. The position peaked at $6.16M in Q3 2020. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

Moore Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Moore Capital Management sold 19,501 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $676K.
Moore Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 5 quarters.
Moore Capital Management's Global Blood Therapeutics, Inc. position peaked at $6.16M in Q3 2020.
195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Moore Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.